

Report to “la Caixa” Foundation


The use of total funds channelled through “la Caixa” Foundation to Gavi programmes in 2022

Executive summary




The partnership

- The “la Caixa” Foundation and GAVI partnership is aimed at protecting the lives of the world’s most disadvantaged children, with a specific focus on **providing life-saving protection against pneumonia** by funding pneumococcal vaccine.



Matching funds

- Thanks to the generosity of the “la Caixa” Foundation, “la Caixa” employees, the Business Alliance for Child Vaccinations, and microdonations from the Spanish public, the Bill and Melinda Gates Foundation have **matched your funds to thus double the impact.**



Impact

- **In 2022, this partnership has channeled USD 3.22 M to Gavi, duplicated to USD 6.44 by BMGF.** These funds have contributed funds to **purchase the equivalent of more than 2.18 M doses estimated** of the pneumococcal vaccine in Mozambique and Ethiopia, sponsoring 100% of disbursements to Pneumo-Mozambique for the year 2022 and 25% of disbursements* to Pneumo-Ethiopia for the years 2021 and 2022.

Content

Report to “la Caixa” Foundation | Year 2022

- 1. Overview of “la Caixa” Foundation partnership contributions**
- 2. Use of funds from LCF and Gavi Matching Fund**
- 3. Background information on Pneumonia Vaccination**



Health worker Emedita arrives with PCV vaccines to the clinic in Mahubo, Mozambique


1

Year 2022

Overview of LCF partnership contributions

Sources of “la Caixa” Foundation contributions in 2022

“la Caixa” Foundation partnership channels funds to Gavi programmes from different sources



LCF contributions and impact in 2022

“la Caixa” Foundation Contributions

USD 3.22 M

“la Caixa” Foundation

USD 1.58M EUR 1.53 M

Business Alliance

USD 1.55M EUR 1.44 M

Employees & Microdonations

USD 0.09M EUR 0.09 M

Gavi Matching Fund

USD 3.22 M

Funds matched by the Bill & Melinda Gates Foundation (BMGF)

Total resources mobilised

USD 6.44 M

Total resourced mobilised in 2022 thanks to the partnership with LCF

All donations were multiplied
by 4

x2 by “la Caixa” Foundation

x2 by BMGF

LCF contributions and impact in 2022




A vaccination session at a health post in Hindane District, Maputo Province, Mozambique.



Elizabeth from Ethiopia is a vibrant example of what vaccinations can achieve: a healthy life that allows children to survive, to flourish and to be educated.

Resources mobilised



- Thanks to the partnership with “la Caixa” Foundation **USD 6.44 M** were mobilised in 2022

Projected Impact



- **2,18 M*** doses of pneumococcal vaccine were purchased.



- Approximately **866,000**** children immunized***

Detailed breakdown of “la Caixa” Foundation funds



Use of funds for pneumococcal vaccines and impact – Year 2022

Mozambique and Ethiopia

	“la Caixa” Foundation**	Employees & Microdonations**	Business Alliance		Total
	Ethiopia	Ethiopia	Ethiopia	Mozambique	
Funds	EUR 1,526,935.09	EUR 86,821.09	EUR 888,437.16	EUR 551,676.84	EUR 3,053,870.18
	USD 1,584,335.71	USD 91,344.47	USD 954,635.88	USD 592,783.06	USD 3,223,099.12
Funds %	50%	3%	29%	18%	100%
Doses purchased*	546,323	31,498	329,185	204,408	1,111,413
Children Immunized	220,000	10,000	130,000	80,000	440,000

*These numbers include a 10% wastage. Total includes possible indicative number of doses purchased with “la Caixa” funds (only).

**The figures regarding the breakdown by source are reported by LCF and audited by a third party, not validated by Gavi. Gavi receives the total amount.

*** Estimated provisional figures, based on previous data. Not for external sharing. Rounded numbers.

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

Detailed breakdown of funds matched by BMGF

Use of funds for pneumococcal vaccines and impact – Year 2022

All Gavi Matching Fund contributions are recorded in US dollars

Mozambique and Ethiopia

	“la Caixa” Foundation**	Employees & Microdonations**	Business Alliance		Total
	Ethiopia	Ethiopia	Ethiopia	Mozambique	
Funds Matched	USD 1,584,335.71	USD 91,344.47	USD 407,403.94	USD 1,140,015.00	USD 3,223,099.12
Funds Matched %	100%	100%	100%	100%	100%
Doses purchased*	536,094	30,908	137,854	367,040	1,071,896****
Children Immunized***	215,000	10,000	55,000	147,000	426,000

*These numbers include a 10% wastage. Total includes possible indicative number of doses purchased with BMGF matching fund funds (only).

**The figures regarding the breakdown by source are reported by LCF and audited by a third party, not validated by Gavi. Gavi receives the total amount.

*** Estimated provisional figures, based on previous data. Not for external sharing. Rounded numbers.

****The number of doses bought from the MF is slightly inferior compared to LCF, even if the US\$ funds are the same, because the MF is also sponsoring the freight. (“la Caixa” Foundation sponsors only the doses)

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

2

Year 2022

Use of funds from LCF and Gavi Matching Fund

Use of “la Caixa” Foundation funds | 2022 Contributions

Financial statement of funds utilization | “la Caixa” Foundation funds - 2022 contribution

Details of contributions received, funds allocated to Gavi programmes, and the balance of contribution

Table 1: 2022 Contributions received as of 31 March 2023

Description or reference	Date of contributions received by Gavi	Amount of contribution received in US\$
2022 Funding from La Caixa Foundation (EUR 1m)	01 December 2022	1,030,000
2022 Funding from Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign, Foundation Matching Fund (EUR 2.1m)	16 February 2023	2,193,099
Total 2022 contributions received as of 31 March 2023		3,223,099

Table 2: Funds allocated to Gavi programmes as of 31 March 2023

Programme description	Implementing country	Number of doses of vaccines	Date of fund allocations	Amount of funds allocated in US\$
Pneumococcal Programmes (CTN 2021-644)	Ethiopia	736,313	19 May 2021	2,135,306
Pneumococcal Programmes (CTN 2022-016)	Ethiopia	170,693	03 November 2021	495,010
Pneumococcal Programmes (CTN 2022-331)	Mozambique	49,299	09 May 2022	142,967
Pneumococcal Programmes (CTN 2022-671)	Mozambique	155,109	10 August 2022	449,816
Total funds allocated to Gavi programmes as of 31 March 2023		1,111,413		3,223,099

Note 1

Note 2

Note 3

Note 4

Table 3: Balance of contribution as of 31 March 2023

Description	Amount in US\$
Total 2022 contributions received, per Table 1 above	3,223,099
Total funds allocated to Gavi programmes, per Table 2 above	-3,223,099
Balance of 2022 contribution as of 31 March 2023	0

Notes:

Note 1 . A portion (US\$ 5,318,020) of CTN 2021-644 was sponsored by La Caixa; with US\$ 3,182,713.64 covered by La Caixa's 2021 contribution, while the remaining US\$ 2,135,306.36 was covered by La Caixa's 2022 contribution.

Note 2. A portion (US\$ 495,010) of CTN 2022-016 was sponsored by La Caixa's 2022 contribution.

Note 3. A portion (US\$ 690,200) of CTN 2022-331 was sponsored by La Caixa, with US\$ 547,233 covered by La Caixa's 2021 contribution, while the remaining US\$ 142,967 was covered by La Caixa's 2022 contribution.

Note 4. A portion (US\$ 1,020,368) of CTN 2022-671 was sponsored by La Caixa, with US\$ 449,816 covered by La Caixa's 2022 contribution, while the remaining US\$ 570,552 is anticipated to be covered by La Caixa's 2023 contribution (yet to be received).

Use of Gavi Matching Fund funds corresponding to the contributions channeled through LCF in 2022

Financial statement of funds utilization | BMGF Matching Fund funds for LCF - 2022 contribution

Details of contributions received, funds allocated to Gavi programmes, and the balance of contribution

Table 1: 2022 Contributions matched by the Gates Matching Fund as of 31 March 2023

Description or reference	Amount of contribution matched in US\$
Gates Matching Funds for 2022 Funding from La Caixa Foundation	1,030,000
Gates Matching Funds for 2022 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign, Foundation Matching Fund	2,193,099
Total 2022 contributions matched by the Gates Matching Fund as of 31 March 2023	3,223,099

Table 2: Funds allocated to Gavi programmes as of 31 March 2023

Programme description	Implementing country	Date of fund allocations	Amount of funds allocated in US\$
Pneumococcal Programmes (CTN 2022-016)	Ethiopia	03 November 2021	2,083,084
Pneumococcal Programmes (CTN 2022-331)	Mozambique	09 May 2022	694,221
Pneumococcal Programmes (CTN 2022-671)	Mozambique	10 August 2022	445,794
Total funds allocated to Gavi programmes as of 31 March 2023			3,223,099

Note 1

Note 2

Table 3: Balance of contributions matched as of 31 March 2023

Description	Amount in US\$
Total 2022 contributions matched, per Table 1 above	3,223,099
Total funds allocated to Gavi programmes, per Table 2 above	-3,223,099
Balance of 2022 contributions matched, as of 31 March 2023	0

Notes:

Note 1. A portion (US\$ 2,443,990) of CTN 2022-016 was sponsored by the Gates Matching Fund on La Caixa; with US\$ 360,907 covered by the Gates Matching Fund on La Caixa's 2021 contribution, while the remaining US\$ 2,083,083 was covered by the Gates Matching Fund on La Caixa's 2022 contribution.

Note 2. A portion (US\$ 1,020,372) of CTN 2022-0671 was sponsored by the Gates Matching Fund on La Caixa; with US\$ 445,794 covered by the Gates Matching Fund on La Caixa's 2022 contribution, while the remaining US\$ 574,578 is anticipated to be covered by the Gates Matching Fund on La Caixa's 2023 contribution (not yet matched).

3

Year 2022

Background information on Pneumonia Vaccination

*This section provides general information on country performance,
beyond the funds provided through the partnership with LCF .*

The challenge: pneumonia and pneumococcal vaccine

Streptococcus pneumoniae is the leading cause of pneumonia – the world's **number one killer of children under five years of age**.



Pneumonia kills more children than any other infectious disease, claiming the lives of over 700,000 children under five every year, or around 2,000 every day¹. Almost all of these deaths are preventable.



The most effective way to prevent these deaths is to ensure that all children have access to safe, affordable vaccines.



Additional risks to children's health and wellbeing surged during the pandemic, with COVID19 causing disruptions throughout the health system as well as to the lives of families. This could result in more severe illness and higher mortality from pediatric pneumonia.



To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.

Pneumonia Vaccination in Mozambique



Notes:

- *All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources*
- *This section describe country performance in general, beyond the funds provided through the partnership with LCF*




Women and their babies at the vaccination clinic at Boane district clinic, in Manhica Province, Mozambique

Progress of the pneumonia Vaccination in Mozambique

Mozambique introduced PCV10 in April 2013 using a three-dose schedule at 2, 3, and 4 months of age. In December 2017, the country switched to PCV13 and a 2+1 schedule to maximize impact.

- **Mozambique has increased the coverage of the PCV3** (Pneumococcal conjugate vaccine, final dose) **from 45% in 2013 to 73% in 2014 and then sustained at 80% coverage in the following years**, until 2020 when the pandemic altered the routine immunization and coverage drooped to 65%. In 2021 the recovery efforts are already reflected in a coverage of 70%.
- **Since 2014, “la Caixa” Foundation has provided over \$22.1 million support towards the procurement of PCV vaccines in Mozambique.** This contribution has been doubled to \$44.2 million thanks to the BMGF Matching Fund. Vaccine procurement is done via UNICEF Supply Division.
- Mozambique performance in PCV vaccine has been driven by:
 - ✓ Strong government commitment towards immunization.
 - ✓ Health systems strengthening investments in data systems, service delivery, demand generation and strengthening of coordination mechanisms.
 - ✓ Strong collaboration between Ministry of Health, core alliance partners (WHO / UNICEF) and multiple expanded partners supporting different technical aspects of the immunization program.



Source: Gavi secretariat based on official data from WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)


Note: All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources.

Impact of the pneumonia Vaccination in Mozambique

Thanks to PCV vaccinations more 22k deaths have been averted in Mozambique since 2014

- From introduction, PCV administration has been timed to coincide with delivery of other routine vaccines (polio, DTP, rotavirus) and other health checks (e.g growth monitoring) thus **increasing uptake and sustaining coverage**.
- From a subnational perspective, **PCV3 coverage is uneven across the country, with northern provinces most affected**. This geographic inequity is indicative of a wider trend for all vaccines, with stock availability a contributing factor.
- To help Mozambique increase its coverage rate, Gavi's plans include:
 - Support the Periodic Intensification of Routine Immunization (PIRI) efforts through financing of operational costs, vaccines and coordination efforts.
 - Technical assistance (Health Systems) to EPI e.g. implementation support; data management skills, electronic Logistics Management Information System (e-LMIS), vaccine forecasting & quantification.
 - Programming the Equity Accelerator Fund support available to Mozambique, which will contribute to the reach of zero-dose children and missed communities.

Estimated Pneumonia deaths averted in Mozambique thanks to PCV vaccinations between 2014 and 2022



Source: VIMC Data Visualisation Tool. <https://montagu.vaccineimpact.org/2021/visualisation/>

Note: All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources.

Pneumonia Vaccination in Ethiopia



Notes:

- *All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources*
- *This section describe country performance in general, beyond the funds provided through the partnership with LCF*




Ethiopia is a country where one in six children dies before reaching their fifth birthday. Vaccinations such as the pneumococcal vaccine are crucial to reducing child mortality.

Progress of the pneumonia Vaccination in Ethiopia

Ethiopia introduced PCV into routine in 2011.

The country successfully switched from PCV10 to PCV13 in 2020.

- **Ethiopia has been able to steadily increase the coverage of the PCV3 (Pneumococcal conjugate vaccine, final dose) from 12% in 2011 to 67% 2020**, when the pandemic and internal conflict altered the routine immunization and coverage dropped to 61%.
- **Since 2021, “la Caixa” Foundation has provided over \$5.8 million support towards the procurement of PCV vaccines in Ethiopia.** This contribution has been doubled to \$11.6 million thanks to BMGF Matching Fund. Vaccine procurement is done via UNICEF Supply Division.
- Ethiopia performance in PCV vaccine has been driven by:
 - ✓ Strong political will and strong political support for immunization.
 - ✓ Immunization structure available to delivery services to the community level
 - ✓ Adequate vaccine storage at national level. The country is using Gavi and other funders to enhance storage capacity at health centre and health post level.



Source: Gavi secretariat based on official data from WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)


Note: All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources.

Impact of the pneumonia Vaccination in Ethiopia

Thanks to PCV vaccinations more 21.9k deaths have been averted in Ethiopia since 2021

- PCV vaccine schedule is the same as the pentavalent vaccines and overlaps with rotavirus and IPV. **This allows for synergies and minimises drop out of children** for the vaccines that are provided at the same time.
- **Conflict affected regions** (Tigray, Amhara, Afar, Oromia, and Benshangul Gumuz) **interrupted immunisation services and led to displacement of people including health workers** in 2021 and 2022. The situation is now stabilising in most of the regions and services are slowly resuming.
- To help Ethiopia increase its coverage rate, Gavi's plans include:
 - Health systems strengthening (HSS) and Equity Accelerator Funding grants.
 - Support efforts to bring immunisation closer to the population in prioritised districts, through increasing frequency of integrated outreach sessions to reach the missed children and communities with services.
 - Providing funding to partners to provide technical assistance aimed at reaching children in hard-to-reach areas and conflict areas as well as strengthening the supply chain.

Estimated Pneumonia deaths averted in Ethiopia thanks to PCV vaccinations between 2021-2022



Source: VIMC Data Visualisation Tool. <https://montagu.vaccineimpact.org/2021/visualisation/>

Note: All impact calculations are estimates. The performance of the different vaccination programs in each country is driven by different factors. Country results are shown at nationwide level, including the support from different sources.

Thank you

All Content in the Gavi Photo Library is copyrighted.
Use of Content in a commercial or promotional context is prohibited.
Adaptation of the Content is prohibited.